CCM2 Antibody

p16 INK4a is a tumor suppressor protein. It is a specific inhibitor of Cdk 4 / Cdk 6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16 INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16 INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16 INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 3 applications: ICC/IF, IF/IHC, WB.

Showing Publications 1 - 2 of 2.

Publications using NBP1-86730	Applications	Species
Abou-Fadel J, Qu Y, Gonzalez Em et Al. Emerging roles of CCM genes during tumorigenesis with potential application as novel biomarkers across major types of cancers Oncol. Rep. 2020-03-18 [PMID: 32186778] (IF/IHC)	IF/IHC
Marchi S, Corricelli M, Trapani E et al. Defective autophagy is a key feature of cerebral cavernous malformations. EMBO Mol Med 2015-11-01 [PMID: 26417067] (ICC/IF, WB)	ICC/IF, WB

Array NBP1-86730

• CCM2 Antibodies
• CCM2 Lysate
• CCM2 Proteins